CIPLA

US FDA placed Pharmathen’s Greece facility under Import Alert 66-40, allowing detention of shipments without inspection. The move escalates earlier compliance issues and risks supply disruption for key products like Lanreotide, a major US revenue contributor, raising concerns over market share loss and earnings impact.